New CAPLYTAо (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented SPRAVATOо (esketamine) effects on anhedonia in treatment-resistant depression (TRD) Ц Phase 3 data post-hoc analyses to be presented Comparative tolerability of adjunctive seltorexant vs. adjunctive quetiapine XR in major depressive disorder (MDD) with insomnia symptoms Ц new Phase 3 metabolic analyses will also be presented TITUSVILLE, N.J., Jan. 13, 2026 /P ...

Core Insights - Johnson & Johnson presented 17 abstracts at the European College of Neuropsychopharmacology (ECNP) Congress, showcasing new clinical and real-world data on major depressive disorder (MDD) and treatment-resistant depression (TRD) [1][2]. Group 1: Major Depressive Disorder (MDD) - MDD affects approximately 332 million people globally, representing about 4% of the population, with around 22 million adults in the U.S. experiencing at least one major depressive episode in 2023 [8]. - The disorder is complex and heterogeneous, with up to 256 unique symptom combinations, leading to varied treatment responses [8]. - Current standard-of-care oral antidepressants leave 2 in 3 patients with residual symptoms, highlighting the need for innovative treatment approaches [8]. Group 2: Treatment-Resistant Depression (TRD) - About one-third of adults with MDD do not respond to oral antidepressants and are classified as having TRD, which significantly impacts their quality of life and has a high economic burden [11]. - The STAR*D study indicates that approximately 86% of patients do not achieve remission after trying their third oral antidepressant [11]. Group 3: New Treatment Data - New analyses from Phase 3 data evaluate the impact of CAPLYTA (lumateperone) on sexual function in MDD patients, suggesting a potential to reset treatment expectations [6]. - A sub-group analysis of Phase 3 data compares the efficacy of adjunctive seltorexant with quetiapine XR in MDD patients with insomnia symptoms [6]. - Findings from the ESCAPE-TRD study explore the association between patient characteristics and remission with SPRAVATO (esketamine) versus quetiapine XR in TRD patients [6]. Group 4: Company Commitment - Johnson & Johnson emphasizes a patient-first approach in developing innovative therapies for MDD and TRD, as stated by the Global Neuroscience Therapeutic Area Head [2].

Core Insights - Johnson & Johnson is presenting 21 abstracts at the U.S. Psychiatric and Mental Health Congress, focusing on major depressive disorder, treatment-resistant depression, and schizophrenia [1][4] - The company emphasizes its commitment to advancing neuroscience and improving patient outcomes through innovative treatments [2][4] Group 1: Major Depressive Disorder (MDD) - MDD affects approximately 332 million people globally, representing about 5% of the population, with around 21 million adults in the U.S. experiencing at least one major depressive episode in 2021 [7][8] - Current treatments often fail to address the unique symptoms of MDD, with 2 in 3 patients continuing to experience residual symptoms despite standard care [7][8] - Insomnia is a common symptom in MDD, affecting about 60% of patients, which can worsen the quality of life and increase the risk of relapse [8] Group 2: Treatment-Resistant Depression (TRD) - Approximately one-third of adults with MDD are classified as having TRD, defined as inadequate response to two or more oral antidepressants [9][10] - The economic burden of TRD is significant, with many patients cycling through multiple medications without achieving remission [10] - The STAR*d study indicates that after trying a third oral antidepressant, about 86% of patients do not achieve remission [10] Group 3: Innovative Treatments - Seltorexant is an investigational therapy being studied as an adjunctive treatment for MDD with insomnia symptoms, aiming to normalize orexin-2 receptor overactivation [13] - CAPLYTA (lumateperone) is approved for treating schizophrenia and bipolar depression, with a supplemental new drug application under review for its use in MDD [11][12] - SPRAVATO (esketamine) is approved for TRD and MDD with suicidal ideation, having been administered to over 150,000 patients worldwide [12][13] Group 4: Schizophrenia Portfolio - Johnson & Johnson offers a comprehensive portfolio of schizophrenia therapies, including long-acting injectables like INVEGA SUSTENNA, INVEGA TRINZA, and INVEGA HAFYERA [14][36] - These treatments provide various dosing options and are designed to support individual patient needs [14][36]